You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
德琪醫藥(06996.HK)與上藥控股就骨髓瘤新藥達成商業化戰略合作
阿思達克 08-13 14:45
德琪醫藥(06996.HK)公布,與上藥控股就口服型選擇性核輸出抑製劑塞利尼索(商品名:XPOVIO / 英文通用名:selinexor)達成商業化戰略合作, 上藥控股將作為德琪醫藥XPOVIO的國內進口總經銷,通過發揮其進口清關、渠道分銷、招標掛網、市場准入等方面經驗,提供一站式進口分銷服務,並借助上藥控股供應鏈服務及合作渠道下的DTP藥房網絡,共同深入探索直接服務患者的DTP藥店、支持患者援助項目PAP藥店及創新金融、商業保險等創新領域。 塞利尼索已於2021年2月24日,獲得中國國家藥品監督管理局的新藥上市申請優先審評資格,用於治療難治復發性多發性骨髓瘤(rrMM)患者。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account